戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 conazole, voriconazole, or posaconazole; and dronedarone.
2 e among patients who received treatment with dronedarone.
3  and liver disease among patients exposed to dronedarone.
4 to investigate the inactivation of CYP450 by dronedarone.
5 regarding clinical efficacy of azimilide and dronedarone.
6 goxin, there were 6 cardiovascular deaths on dronedarone (1.7%/year) and 8 on placebo (2.2%/year; adj
7          The electrophysiological effects of dronedarone (10 mumol/l) and a relatively low concentrat
8 ebo (P=0.008), whereas ranolazine 750 mg BID/dronedarone 150 mg BID reduced AFB by 43% (P=0.072).
9            Conversely, ranolazine 750 mg BID/dronedarone 225 mg BID reduced AFB by 59% versus placebo
10 We identified 4 placebo-controlled trials of dronedarone, 4 placebo-controlled trials of amiodarone,
11 Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascu
12 ol 66%, flecainide 68%, propafenone 48%, and dronedarone 80%.
13        Of these, 4,856 patients had received dronedarone according to the Swedish Drug Register, and
14    We analyzed changes in physicians' use of dronedarone after the PALLAS trial showed that dronedaro
15 d to placebo, ranolazine alone (750 mg BID), dronedarone alone (225 mg BID), or one of the combinatio
16 ntration on day 7 was 1.1 (0.7,1.5) ng/mL on dronedarone and 0.7 (0.5,1.1) ng/mL on placebo (P<0.001)
17  In PALLAS, 1619 patients were randomized to dronedarone and 1617 to placebo, of whom 544 (33.6%) and
18 were 15 (8.6%/year) cardiovascular deaths on dronedarone and 2 (1.2%/year) on placebo (adjusted hazar
19 matched cohort comprised 6212 patients (3106 dronedarone and 3106 sotalol; mean [+/-SD] age, 71+/-10
20 n digoxin, there were 2 arrhythmic deaths on dronedarone and 4 on placebo (P value for interaction 0.
21 on are 2.19 microM and 0.0056 minute(-1) for dronedarone and 5.45 microM and 0.056 minute(-1) for NDB
22 We demonstrated for the first time that both dronedarone and its main metabolite N-desbutyl dronedaro
23                               In conclusion, dronedarone and NDBD inactivate CYP3A4 and CYP3A5 via un
24  both CYP3A4 and CYP3A5 from inactivation by dronedarone and NDBD.
25 ived from the quinone oxime intermediates of dronedarone and NDBD.
26  digoxin, there were 11 arrhythmic deaths on dronedarone and none on placebo; and in patients not on
27                           The combination of dronedarone and ranolazine caused little change in actio
28 aluate the effectiveness of a combination of dronedarone and ranolazine in suppression of atrial fibr
29 that raise questions regarding the safety of dronedarone and several new promising techniques in AF a
30 jection fraction was 55+/-11 and 58+/-10 for dronedarone and sotalol users, correspondingly.
31            New antiarrhythmic drugs, such as dronedarone and vernakalant, have provided some addition
32 croM and 0.039 minute(-1), respectively, for dronedarone, and 6.24 microM and 0.099 minute(-1), respe
33  summarize the available evidence concerning dronedarone, and offer practical recommendations to heal
34 for the inactivation of CYP3A4 and CYP3A5 by dronedarone are 51.1 and 32.2, and the partition ratios
35                                  Sotalol and dronedarone are both used for maintenance of sinus rhyth
36          The electrophysiological effects of dronedarone are similar to those of AM but more potent,
37 ctive investigation, including azimilide and dronedarone, are compounds with multiple electrophysiolo
38                                              Dronedarone, as prescribed to AF patients in Sweden, has
39 hysicians decreased their quarterly usage of dronedarone by 0.12 percentage points more per quarter (
40                                              Dronedarone caused little or no change in electrophysiol
41                                              Dronedarone, compared with sotalol, did not demonstrate
42                                              Dronedarone, compared with sotalol, was associated with
43    The present analysis examines whether the dronedarone-digoxin interaction might explain these adve
44 oring for QT prolongation and proarrhythmia, dronedarone does not.
45 olazine (750 mg BID) combined with 2 reduced dronedarone doses (150 mg BID and 225 mg BID; chosen to
46   There has been concern about the safety of dronedarone, especially for patients with heart failure
47 twork connections were faster de-adopters of dronedarone for patients with permanent atrial fibrillat
48 lack box warning detailed the harmfulness of dronedarone for these patients.
49 oup and 102.3+/-24.7 beats per minute in the dronedarone group (P<0.001); the corresponding rates in
50 days in the placebo group and 96 days in the dronedarone group (P=0.01).
51 tion were not significantly increased in the dronedarone group.
52 ustment for cofactors, patients who received dronedarone had lower mortality than other AF patients (
53 ad the lowest risk of AF hospitalization and dronedarone had the greatest risk.
54 view evidence of safety and effectiveness of dronedarone in patients with atrial fibrillation.
55 e that the available data support the use of dronedarone in select patient populations as a second- o
56 onedarone after the PALLAS trial showed that dronedarone increased the risk of death from cardiovascu
57                                              Dronedarone increases digoxin concentration by P-glycopr
58 of the underlying mechanisms associated with dronedarone-induced hepatotoxicity and clinical drug-dru
59 in-house preliminary study demonstrated that dronedarone inhibits cytochrome P450 (CYP) 3A4 and 3A5 i
60        For every 1,000 patients treated with dronedarone instead of amiodarone, we estimate approxima
61                                              Dronedarone is a new antiarrhythmic agent pharmacologica
62                                              Dronedarone is a new antiarrhythmic agent that was recen
63                                              Dronedarone is a noniodinated amiodarone congener develo
64                                              Dronedarone is a noniodinated benzofuran derivative of a
65                       Similar to amiodarone, dronedarone is a potent blocker of multiple ion currents
66                                              Dronedarone is an antiarrhythmic agent approved in 2009
67                                              Dronedarone is less effective than amiodarone for the ma
68 onedarone and its main metabolite N-desbutyl dronedarone (NDBD) inactivate CYP3A4 and CYP3A5 in a tim
69 ible metabolite-intermediate complex between dronedarone/NDBD and CYP3A4/CYP3A5, partial recovery of
70 current digoxin use on the adverse effect of dronedarone on cardiovascular death, but not on occurren
71 seline digoxin use and the adverse effect of dronedarone on heart failure events.
72 nent Atrial Fibrillation Outcome Study Using Dronedarone On Top Of Standard Therapy Trial (PALLAS), d
73 clinical trials have evaluated the impact of dronedarone on various cardiovascular end points and yie
74                                  Separately, dronedarone or a low concentration of ranolazine prevent
75 rolled trials in which the authors evaluated dronedarone or amiodarone for the prevention of AF.
76 patients with atrial fibrillation prescribed dronedarone or sotalol in 2012 or later.
77  trial evidence found amiodarone superior to dronedarone (OR: 0.49; 95% CI: 0.37 to 0.63; p < 0.001)
78  drug discontinuation with amiodarone versus dronedarone (OR: 1.81; 95% CI: 1.33 to 2.46; p < 0.001).
79 first AAD prescription (amiodarone, sotalol, dronedarone, or Class Ic) within 14 days post-first AF e
80                                              Dronedarone patients with heart failure had lower mortal
81         Low concentrations of ranolazine and dronedarone produce relatively weak electrophysiological
82                                              Dronedarone reduces mortality and morbidity in patients
83 yclosporine; erythromycin or clarithromycin; dronedarone; rifampin; or phenytoin.
84 (150 mg BID and 225 mg BID; chosen to reduce dronedarone's negative inotropic effect-see text below)
85  amiodarone (AM), its noniodinated analogue, dronedarone (SR), was synthesized.
86                                              Dronedarone, tedisamal, and trecetilide are now under ac
87  risk of AF hospitalization was greater with dronedarone than Class Ic (hazard ratio [HR] 1.59; 95% c
88 he impact of the PALLAS trial on physicians' dronedarone usage between 2009 and 2014.
89 sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recu
90  directly compare the efficacy and safety of dronedarone versus amiodarone.
91 trolled trials of amiodarone, and 1 trial of dronedarone versus amiodarone.
92 fidence interval [CI]: 0.08 to 0.19) but not dronedarone versus placebo (OR: 0.79; 95% CI: 0.33 to 1.
93 l mortality rate among patients who received dronedarone was 1.3% compared with 14.0% in the control
94 e On Top Of Standard Therapy Trial (PALLAS), dronedarone was associated with both increased cardiovas
95                                     However, dronedarone was associated with significantly lower risk
96          Before the PALLAS trial, the use of dronedarone was increasing by 0.22 percentage points per
97                                              Dronedarone was significantly more effective than placeb
98              The effect of amiodarone versus dronedarone was summarized by the use of indirect compar
99                          Patients prescribed dronedarone were younger (age 65.5 years vs. 75.7 years,
100 y moderate dose ranolazine plus reduced dose dronedarone, with good tolerance/safety, in the populati